Sensorion Appoints Pharmaceutical Industry Veteran Scott D. Myers Chairman of the Board and Independent Director


MONTPELLIER, France, December 20, 2021– (COMMERCIAL THREAD) – Regulatory news:

Sensorion (Paris: ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director .

Scott, who is also Chairman of the Board of Directors of Dynavax Technologies (NASDAQ: DVAX) and Harpoon Therapeutics (NASDAQ: HARP), brings to Sensorion nearly 30 years of global experience in the pharmaceutical and medical technology industries.

Previously, Mr. Myers was CEO and CEO of AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), where he led its turnaround and strategic sale to Covis Pharma, in November 2020. He also served as Chairman of the Board directors and CEO. of Rainier Therapeutics, an oncology biotechnology company specializing in the treatment of advanced bladder cancer, where he led the sale of Vofatamab to Fusion Pharmaceuticals (FUSN). He was previously CEO, President and Director of Oncology Company Cascadian Therapeutics (CASC) from April 2016 until its acquisition by Seattle Genetics in March 2018. He was also an Independent Director of Trillium Therapeutics (TRIL) until its acquisition by Pfizer (PFE) in September 2021. In addition to his role at Dynavax and Harpoon, he is currently an independent director of the board of directors of Selecta Biosciences (SELB). He holds a Bachelor of Arts in Biology from Northwestern University and an MBA from the Booth School of Business at the University of Chicago.

Scott will succeed Edwin Moses, who is stepping down from Sensorion’s board on December 19 to focus on his portfolio of other commitments.

Nawal Ouzren, CEO of Sensorion, commented : “We are delighted to welcome Scott as the new President. Its extensive world-class experience, spanning clinical research and development, partnerships, regulation and commercialization, will be essential as Sensorion continues to develop its pipeline and international presence. I have known Scott for many years and look forward to his strategic advice as we move forward on our journey to make a lasting positive impact for patients worldwide with inner ear disorders.

“I would like to thank Edwin on behalf of the Board of Directors, and personally, for his valued leadership and contributions to Sensorion.”

Scott myers added: “I am delighted to take on the role of President in this exciting phase of Sensorion’s development. I look forward to working with the Board of Directors and Management to further Sensorion’s pioneering work to develop new therapies to restore, treat and prevent hearing loss disorders. “

Edwin Moses commented : “I am proud to have been President of Sensorion. The company has grown and developed its exciting portfolio of new therapies for hearing loss disorders. I look forward to seeing Sensorion’s continued success. “

About Sensorion
Sensorion is a pioneering clinical-stage biotechnology company specializing in the development of new therapies to restore, treat and prevent hearing loss disorders. Its clinical-stage portfolio includes a phase 2 product: SENS-401 (Arazasetron) for sudden sensorineural hearing loss (SSNHL). Sensorion has built a unique R&D technology platform to broaden its understanding of the pathophysiology and etiology of inner ear-related diseases, enabling it to select the best targets and modalities for drug candidates. The Company is also working to identify biomarkers to improve the diagnosis of these underserved diseases. Sensorion has launched three gene therapy programs, currently at the preclinical stage, aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation in the gene encoding Otoferlin, hearing loss linked to the target gene GJB2 as well as the syndrome. Usher Type 1 to potentially treat important segments of hearing loss in adults and children. The Company is potentially in a unique position, through its platforms and pipeline of potential therapies, to have a lasting positive impact on hundreds of thousands of people with inner ear disorders, a significant global medical need not satisfied.

follow us on Linkedin

IS IN: FR0012596468
Mnemonic: ALSEN

This press release contains certain forward-looking statements regarding Sensorion and its activities. These forward-looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that these forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set out in the 2020 annual financial report published on April 9, 2021 and available on our website and under changing conditions. economic, financial markets and markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or currently considered insignificant by Sensorion. The occurrence of all or part of these risks could cause the actual results, financial conditions, performance or achievements of Sensorion to differ materially from these forward-looking statements. This press release and the information it contains do not constitute an offer to sell or subscribe, nor a solicitation of an offer to buy or subscribe to Sensorion shares in any country whatsoever. The distribution of this press release in certain countries may constitute a violation of local laws and regulations. Anyone who receives this press release should inform themselves about and comply with these local restrictions.

See the source version on


Investor Relations
Catherine leveau
Head of Investor Relations & Communication
[email protected]
+ 33 6 72 18 00 22

International media relations
Strategic Communication Consilium
Mary-Jane Elliott / Jessica Hodgson
+ 44 7739 788014
+44 7561 424788
[email protected]


About Author

Comments are closed.